--- title: "Aytu BioPharma (AYTU) news: lawsuit" url: "https://aibio.space/companies/aytu-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AYTU lawsuit news: Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial. Aytu BioPharma, Inc. (NASDAQ: AYTU), United States." --- AYTU Aytu BioPharma, Inc. NASDAQ · United States # Aytu BioPharma (AYTU) news AYTU lawsuit news Legal · 2026-09-22 ## [Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial](https://aibio.space/news/aytu-biopharmas-adzenys-patent-suit-against-granules-heads-january/) Aytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal. ## Latest Aytu BioPharma news 1. 2025-06-23 Debt Financing [Aytu BioPharma extends Eclipse term loan and revolver to 2029, adds $1.5 million advance](https://aibio.space/news/aytu-biopharma-extends-eclipse-term-loan-revolver-2029-adds-1-5/) Amendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%. 2. 2025-06-06 Mergers [Aytu BioPharma signs EXXUA commercialization deal with Fabre-Kramer, pays $3,000,000 upfront](https://aibio.space/news/aytu-biopharma-signs-exxua-commercialization-deal-fabre-kramer-pays-3/) Aytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million. 3. 2025-06-06 Mergers [Aytu BioPharma pays $3,000,000 upfront for U.S. rights to depression drug EXXUA](https://aibio.space/news/aytu-biopharma-pays-3-000-000-upfront-u-s-rights-depression-drug-exxua/) Aytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales. ## Aytu BioPharma at a glance - **Ticker**: AYTU - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $26.3 million ### Related companies - [Cerenome](https://aibio.space/companies/cerenome/) NASDAQ: CNSY - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) NASDAQ: RLMD - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) NASDAQ: ZVRA - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) NASDAQ: MGRX - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) NASDAQ: GYRE - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Shuttle Pharmaceuticals Holdings](https://aibio.space/companies/shuttle-pharmaceuticals/) NASDAQ: SHPH ### Also on NASDAQ - [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) ANGO - [NEPHROS INC](https://aibio.space/companies/nephros/) NEPH - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) SCTX - [Innovative Eyewear](https://aibio.space/companies/innovative-eyewear/) LUCY - [Ardelyx](https://aibio.space/companies/ardelyx/) ARDX - [Entera Bio](https://aibio.space/companies/entera-bio/) ENTX ## What Aytu BioPharma does Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. Its main focus is EXXUA (gepirone) extended-release tablets, which it commercializes in the United States under an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. entered into in June 2025. The text describes EXXUA as a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for major depressive disorder in adults. Aytu also sells a prescription ADHD portfolio, Adzenys XR-ODT and Cotempla XR-ODT, and the Pediatric Portfolio product Karbinal ER. Its products are sold primarily through third-party wholesalers and pharmacies. The company has indefinitely suspended active development of its clinical programs, including AR101 (enzastaurin), and wound down and divested its Consumer Health business. | Product or program | What it is | Stage | |---|---|---| | EXXUA (gepirone) extended-release tablets | Treatment of major depressive disorder in adults, commercialized in the United States | approved by the FDA | | Adzenys XR-ODT and Cotempla XR-ODT | ADHD extended-release orally disintegrating tablets with authorized generic equivalents | sold through third-party wholesalers and pharmacies | | Karbinal ER | Extended-release carbinoxamine oral suspension for numerous allergic conditions | sold through third-party wholesalers and pharmacies | | AR101 (enzastaurin) | Clinical program for which active development is indefinitely suspended | development suspended | Summarised from the company's [10-K filed Sep 22, 2026](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm). ## Aytu BioPharma annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$0](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | | Net income (loss) | [-$14.3 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | [-$13.6 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | | Cash from operations | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | [-$1.9 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | | Cash and equivalents | [$26.3 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | [$31.0 million](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $26.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aytu BioPharma Is Aytu BioPharma involved in a lawsuit? Our latest story on this, dated Sep 22, 2026: "Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aytu-biopharmas-adzenys-patent-suit-against-granules-heads-january/). What is the ticker symbol of Aytu BioPharma? Aytu BioPharma, Inc. trades under the ticker AYTU on NASDAQ. Where is Aytu BioPharma listed? Aytu BioPharma, Inc. is listed on NASDAQ. What is the SEC CIK of Aytu BioPharma? The SEC Central Index Key (CIK) for Aytu BioPharma, Inc. is 1385818. Its filings are on SEC EDGAR. How many shares does Aytu BioPharma have outstanding? 10,866,708 shares as of 2026-09-15, per the cover page of its 10-K filed 2026-09-22. Which country or territory is Aytu BioPharma listed under? Our directory records Aytu BioPharma, Inc. under United States. What does Aytu BioPharma do? Our directory classifies Aytu BioPharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Aytu BioPharma? The ISIN recorded for Aytu BioPharma, Inc. is US0547548588. Does aibio.space cover Aytu BioPharma? aibio.space lists Aytu BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aytu BioPharma incorporated? SEC records list its state or country of incorporation as DE. What does Aytu BioPharma develop? Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. Its main focus is EXXUA (gepirone) extended-release tablets, which it commercializes in the United States under an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. entered into in June 2025. What is EXXUA (gepirone) extended-release tablets from Aytu BioPharma? EXXUA (gepirone) extended-release tablets: Treatment of major depressive disorder in adults, commercialized in the United States Stage: approved by the FDA. What is Adzenys XR-ODT and Cotempla XR-ODT from Aytu BioPharma? Adzenys XR-ODT and Cotempla XR-ODT: ADHD extended-release orally disintegrating tablets with authorized generic equivalents Stage: sold through third-party wholesalers and pharmacies. Is Aytu BioPharma profitable? Aytu BioPharma, Inc. reported a net loss of $14.3 million for the fiscal year ended Jun 30, 2026, and generated $3.3 million of cash from operations, per its annual report to the SEC. How much does Aytu BioPharma spend on research and development? $0 in the fiscal year ended Jun 30, 2026, per its annual report. ## Investor discussion: Aytu BioPharma Members talk about Aytu BioPharma (AYTU). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aytu BioPharma, newest first. Each line links the filing it comes from. 1. 2026-06-25 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774926021707/aytu20260624c_8k.htm) 2. 2026-04-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,3.02,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/aytu20260327_8k.htm) 3. 2025-08-07 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774925025441/aytu20250617_8k.htm) 4. 2025-06-06 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774925019718/aytu20250523c_8k.htm) 5. 2025-06-02 Financings Filed a final prospectus for a securities offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774925019189/aytu20250530_s1.htm) 6. 2024-12-04 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1385818/000143774924036630/aytu20241203_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AYTU on TradingView](https://www.tradingview.com/symbols/NASDAQ-AYTU/). ## SEC filings and registration - **SEC name**: Aytu Biopharma, Inc - **CIK**: 1385818 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AYTU (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 7900 E. UNION AVENUE, DENVER, CO, 80237 - **Phone**: (720) 437-6580 - **Shares outstanding**: 10,866,708 as of 2026-09-15 (10-K filed 2026-09-22) - **Former names**: AYTU BIOSCIENCE, INC; Rosewind CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1385818/000143774926033276/aytu20260817_def14a.htm) filed 2026-10-22 - [10-K](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/aytu20260502_8k.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1385818/000143774926021707/aytu20260624c_8k.htm) filed 2026-06-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1385818/000143774926016721/aytu20260331_10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/aytu20260209_8k.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/aytu20260327_8k.htm) filed 2026-04-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1385818/000143774926002804/aytu20251231_10q.htm) filed 2026-02-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001385818), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aytu BioPharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AYTU, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aytu BioPharma, Inc. - **Ticker**: AYTU - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0547548588 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AYTU/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aytu-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aytu BioPharma (AYTU) news: lawsuit", 2026-10-31, https://aibio.space/companies/aytu-biopharma/